Discovering the Italian Biotech Industry
The last report on the Italian biotech industry, drafted thanks to the consolidated collaboration between Assobiotec (Italian Association for the Development of Biotechnology, part of Federchimica) and ENEA (National Agency for New Technologies, Energy and Sustainable Economic Development), has been published in May 2019. The analysis offers an update on the current Italian biotech industry in 2018.
The work presents analysis and estimates based on information provided by the firms operating in the sector at the end of 2018, their 2017 financial statements, public data and data from the National Statistical System.
The data, collected within the framework of the National Statistical Programme, will feed into the key biotechnology indicators produced by the OECD - Organization for Economic Cooperation and Development, whose methodology is adopted in this study.
During the last 3 years, the total number of biotech firms remained pretty much stable, while the turnover generated by biotech activity grew by 16%, more than double the rate of the manufacturing sector (7%).
During the same period of time, the biotech R&D investment increased by 17%, and the biotech employees, nearing the 13,000 units, rose by 15% within the national-owned dedicated biotech R&D firms. The share of small and micro enterprises represents the 78% of the Italian biotech firms and, therefore, the biotech sector shows a higher average company size than the manufacturing sector.
To sum up, the Italian biotech sector continues to grow in all its main economic indicators and to be research-intensive, experiencing a consolidation phase in terms of number of firms. All of this, in spite of the fact that the sector has been waiting for a long time the setting up of a national strategy in favour of medium-long term research and innovation, to unlock its full potential for our country in terms of competitiveness, occupation and well-being.